BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//6.0.1.1//EN
BEGIN:VEVENT
UID:1742d490-ae02-4d7f-8aea-0e8922d5a679
DTSTART:20260819T080000Z
DTEND:20260821T170000Z
DTSTAMP:20260501T080024Z
SUMMARY:6th Oligonucleotides for CNS Summit 2026
DESCRIPTION:Oligonucleotide R and D is accelerating\, driven by advances in brain shuttle technologies\, RNA chemistry\, and growing clinical validation from leaders such as Alnylam Pharmaceuticals\, Stoke Therapeutics\, and Ionis Pharmaceuticals. At the same time\, major investments\, including Novartis into Arrowhead Pharmaceuticals\, Biogen into City Therapeutics\, and Roche into Manifold Bio\, underscore CNS as a key frontier for these technologies\, unlocking previously undruggable targets.\n\nBuilding on last year's momentum\, the 6th Annual Oligonucleotides for CNS Summit will bring together 160+ experts across CNS biology\, oligo chemistry\, RNA science\, and DMPK. Attendees will explore the latest innovations advancing nucleic acid therapies for neurodegenerative\, neuromuscular\, rare\, epileptic\, and neurodevelopmental disorders.\n\nThis summit uniquely connects stakeholders at the intersection of oligonucleotides and CNS. Join leaders from Eli Lilly\, Dyne Therapeutics\, Creyon Bio\, and more for three days of collaboration to accelerate RNA-targeted CNS therapies.
LOCATION:The Colonnade Hotel\, 120 Huntington Avenue\, Boston\, Massachusetts\, 02116\, United States
URL:https://eventstopten.com/events/6th-oligonucleotides-for-cns-summit-2026/
END:VEVENT
END:VCALENDAR